Skip to main content

Table 6 Impact of the program on the reporting of at least one adverse drug event by patients, and by patients and/or General Practitioners (N = 908 patients)

From: Improving patient self-reporting of antihypertensive adverse drug events in primary care: a stepped wedge cluster randomised trial

 

Patient self-reporting of ADE

Patient and/or GP reporting of ADE

aOR

95% CI

p-value

aOR

95% CI

p-value

Program

3.5

1.2–10.1

0.02

2.5

1.3–5.1

0.01

Perioda

0.8

0.6–1.2

0.31

0.7

0.6–0.9

0.02

Ageb

1.0

1.0–1.1

0.06

1.0

1.0–1.0

0.21

Sex M

0.9

0.5–1.8

0.86

0.8

0.5–1.2

0.22

Educational level

    

–

–

 Secondary school or no diploma

1.0

–

–

1.0

  

 Vocational/High-school degree

0.8

0.4–1.9

0.67

1.1

0.7–1.9

0.69

 University degree

1.5

0.6–3.4

0.38

1.1

0.6–1.9

0.85

Morbidity ≥3 chronic pathologies

0.8

0.2–3.6

0.78

1.4

0.6–3.1

0.45

Situations with a risk of ADEs

0.5

0.2–1.7

0.28

0.6

0.3–1.3

0.18

Antihypertensive prescription:

 Renewal

1.0

–

–

1.0

–

–

 Modification

4.4

1.9–10.0

< 0.001

4.1

2.3–7.3

< 0.001

 Initiation

11.0

4.6–26.4

<  0.001

17.7

8.9–35.4

< 0.001

  1. ADE adverse drug event
  2. Chronic pathologies: heart failure, heart rhythm disorder, anchor, myocardial infarction, obliterating arteriopathy of the lower limbs, renal artery stenosis, diabetes, cerebrovascular accident, COPD or chronic respiratory failure, asthma, cirrhosis or liver failure, renal failure (creatinine clearance < 60 ml/min), gout, cancer, depression, Parkinson
  3. Situations presenting a risk of antihypertensive drug-related ADEs: hypotension, fever, nutritional depletion, diarrhoea, nausea, vomiting, abdominal pain, heat period, reduced mobility, recent malaise, recent fall
  4. afrom one period to another
  5. bfor a one year increase